Vicor to start trial of PD2i Analyzer in concussion
This article was originally published in Clinica
Executive Summary
Vicor Technologies is planning to assess its PD2i Analzyer, which measures heart rate variability, in a trial of concussion in athletes. It has received Institutional Review Board approval from the first site, the University of Mississippi Medical Center. The study aims to assess whether the device can help determine the extent of concussion and the risk of subsequent adverse events. The PD2i Analzyer received 510(k) clearance from the US FDA in January 2009, but this is the first time it has been studied in concussion. Boca Raton, Florida-based Vicor has also developed PD2i CA (Cardiac Analyzer), to identify patients at increased risk of cardiac death, which it filed with the FDA in July (www.clinica.co.uk, 6 July 2010).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.